Cargando…

Risk of Immune-Related Pancreatitis in Patients with Solid Tumors Treated with Immune Checkpoint Inhibitors: Systematic Assessment with Meta-Analysis

We performed a systematic review and meta-analysis to determine the risk of immune-related pancreatitis associated with the treatment by immune checkpoint inhibitors (ICIs) for solid tumors. Eligible studies were selected from multiple databases including phase II/III randomized controlled trials (R...

Descripción completa

Detalles Bibliográficos
Autores principales:	Su, Qiang, Zhang, Xiao-chen, Zhang, Chen-guang, Hou, Yan-li, Yao, Yu-xia, Cao, Bang-wei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2018
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6008648/ https://www.ncbi.nlm.nih.gov/pubmed/29971244 http://dx.doi.org/10.1155/2018/1027323

Ejemplares similares

Risk of Pneumonitis and Pneumonia Associated With Immune Checkpoint Inhibitors for Solid Tumors: A Systematic Review and Meta-Analysis
por: Su, Qiang, et al.
Publicado: (2019)

Pancreatic adverse events in patients treated with immune checkpoint inhibitors
por: Hana, Caroline, et al.
Publicado: (2023)

Predictive impact of sarcopenia in solid cancers treated with immune checkpoint inhibitors: a meta‐analysis
por: Takenaka, Yukinori, et al.
Publicado: (2021)

ICU admission for solid cancer patients treated with immune checkpoint inhibitors
por: Toffart, Anne-Claire, et al.
Publicado: (2023)

Cytomegalovirus Infections in Patients Treated With Immune Checkpoint Inhibitors for Solid Malignancies
por: Anastasopoulou, Amalia, et al.
Publicado: (2023)

Prevalence of PRKDC mutations and association with response to immune checkpoint inhibitors in solid tumors
por: Chen, Yu, et al.
Publicado: (2020)

Geographic heterogeneity in the outcomes of patients receiving immune checkpoint inhibitors for advanced solid tumors: a meta-analysis
por: Li, Manyu, et al.
Publicado: (2021)

Pancreatic adverse events of immune checkpoint inhibitors therapy for solid cancer patients: a systematic review and meta-analysis
por: Zhao, Zhe, et al.
Publicado: (2023)

The Lung Immune Prognostic Index Discriminates Survival Outcomes in Patients with Solid Tumors Treated with Immune Checkpoint Inhibitors
por: Meyers, Daniel E., et al.
Publicado: (2019)

Increasing cure rates of solid tumors by immune checkpoint inhibitors
por: Ma, Weijie, et al.
Publicado: (2023)

Hyperprogressive disease in patients suffering from solid malignancies treated by immune checkpoint inhibitors: A systematic review and meta-analysis
por: Zhao, Zijun, et al.
Publicado: (2022)

Association of MUC16 Mutation With Response to Immune Checkpoint Inhibitors in Solid Tumors
por: Zhang, Lei, et al.
Publicado: (2020)

Fatal Immune Checkpoint Inhibitor-related Pancreatitis
por: Ueno, Masayuki, et al.
Publicado: (2021)

Efficacy and safety of oncolytic virus combined with chemotherapy or immune checkpoint inhibitors in solid tumor patients: A meta-analysis
por: Liu, Xiangxing, et al.
Publicado: (2022)

Risk of Cardiac Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-Analysis
por: Hu, Jiexuan, et al.
Publicado: (2021)

How Can Immune Checkpoint Inhibitors Cause Hyperprogression in Solid Tumors?
por: Denis, Morgane, et al.
Publicado: (2020)

Retreatment with immune checkpoint inhibitors in solid tumors: a systematic review
por: Yang, Kaili, et al.
Publicado: (2020)

Repurposing drugs for solid tumor treatment: focus on immune checkpoint inhibitors
por: Liu, Qingxu, et al.
Publicado: (2023)

Pancreatic injury following immune checkpoint inhibitors: A systematic review and meta-analysis
por: Zhang, Tian, et al.
Publicado: (2022)

Prognostic Role of Tumor Mutational Burden in Cancer Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
por: Huang, Taobi, et al.
Publicado: (2021)

Changes in circulating tumor DNA and outcomes in solid tumors treated with immune checkpoint inhibitors: a systematic review
por: Al-Showbaki, Laith, et al.
Publicado: (2023)

ATM Mutations Benefit Bladder Cancer Patients Treated With Immune Checkpoint Inhibitors by Acting on the Tumor Immune Microenvironment
por: Yi, Ruibin, et al.
Publicado: (2020)

Clinical Potential of Kinase Inhibitors in Combination with Immune Checkpoint Inhibitors for the Treatment of Solid Tumors
por: Ahn, Ryuhjin, et al.
Publicado: (2021)

Risk Factors, Incidence, and Prognosis of Thromboembolism in Cancer Patients Treated With Immune Checkpoint Inhibitors
por: Zou, Xue-lin, et al.
Publicado: (2021)

Immune-related pneumonitis associated with immune checkpoint inhibitors in lung cancer: a network meta-analysis
por: Chen, Xinru, et al.
Publicado: (2020)

Immune Checkpoint Inhibitors to Treat Malignant Lymphomas
por: Witkowska, Magdalena, et al.
Publicado: (2018)

Coexistence of Immune Checkpoint Inhibitor-Induced Autoimmune Diabetes and Pancreatitis
por: Zhang, Amy L., et al.
Publicado: (2021)

Interrogating the immune-modulating roles of radiation therapy for a rational combination with immune-checkpoint inhibitors in treating pancreatic cancer
por: Fujiwara, Kenji, et al.
Publicado: (2020)

Patterns and outcomes of immune-related adverse events in solid tumor patients treated with immune checkpoint inhibitors in Thailand: a multicenter analysis
por: Ngamphaiboon, Nuttapong, et al.
Publicado: (2021)

Preexisting autoantibodies as predictor of immune related adverse events (irAEs) for advanced solid tumors treated with immune checkpoint inhibitors (ICIs)
por: Daban, A, et al.
Publicado: (2023)

Infectious complications of immune checkpoint inhibitors in solid organ malignancies
por: Ross, Justine Abella, et al.
Publicado: (2021)

Immune Checkpoint Inhibitor-Induced Acute Pancreatitis and Colitis
por: Pagan, Andrea, et al.
Publicado: (2020)

Two Types of Immune Checkpoint Inhibitor-related Pancreatitis
por: Ichiki, Tomoko, et al.
Publicado: (2021)

Comparing organ‐specific immune‐related adverse events for immune checkpoint inhibitors: A Bayesian network meta‐analysis
por: Li, Meichen, et al.
Publicado: (2021)

Immune Checkpoint Inhibitor-Associated Cardiotoxicity in Solid Tumors: Real-World Incidence, Risk Factors, and Prognostic Analysis
por: Chen, Xue, et al.
Publicado: (2022)

CCND1 Amplification Contributes to Immunosuppression and Is Associated With a Poor Prognosis to Immune Checkpoint Inhibitors in Solid Tumors
por: Chen, Yu, et al.
Publicado: (2020)

Changes of Immune Cell Fractions in Patients Treated with Immune Checkpoint Inhibitors
por: Kim, Hye Ryeon, et al.
Publicado: (2022)

Incidence of Immune-Mediated Pseudoprogression of Lymphoma Treated with Immune Checkpoint Inhibitors: Systematic Review and Meta-Analysis
por: Lee, Amy Junghyun, et al.
Publicado: (2021)

Predictors of Response and Survival in Immune Checkpoint Inhibitor-Treated Unresectable Hepatocellular Carcinoma
por: Lee, Pei-Chang, et al.
Publicado: (2020)

The Prediction Potential of the Pretreatment Lung Immune Prognostic Index for the Therapeutic Outcomes of Immune Checkpoint Inhibitors in Patients With Solid Cancer: A Systematic Review and Meta-Analysis
por: Liu, Hui, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_bjqsaum8s4tr98mpte3tf5nlj9